David Erlinge
Overview
Explore the profile of David Erlinge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
423
Citations
9162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Erlinge D, Andersson J, Frobert O, Tornerud M, Hamid M, Kellerth T, et al.
Lancet
. 2024 Oct;
404(10464):1750-1759.
PMID: 39481425
Background: Persistent non-plateauing adverse event rates in patients who underwent percutaneous coronary intervention (PCI) remain a challenge. A bioadaptor is a novel implant that addresses this issue by restoring the...
12.
Petursson P, Gudmundsson T, Ramunddal T, Angeras O, Rawshani A, Mohammad M, et al.
Eur Heart J Cardiovasc Pharmacother
. 2024 Oct;
11(1):57-65.
PMID: 39415431
Background: The use of inotropic agents in treating cardiogenic shock (CS) remains controversial. This study investigates the effect of inotropes on 30-day mortality in CS patients using data from the...
13.
Bhatty A, Wilkinson C, Batra G, Aktaa S, Smith A, Wahab A, et al.
Eur Heart J Qual Care Clin Outcomes
. 2024 Oct;
PMID: 39384575
Aims: The lack of standardised definitions for heart failure outcome measures limits the ability to reliably assess effectiveness of heart failure therapies. The European Unified Registries for Heart Care Evaluation...
14.
Stone G, Valgimigli M, Erlinge D, Han Y, Steg P, Stables R, et al.
J Am Coll Cardiol
. 2024 Oct;
84(16):1512-1524.
PMID: 39384262
Background: In the BRIGHT-4 (Bivalirudin With Prolonged Full-Dose Infusion During Primary PCI Versus Heparin Trial-4), anticoagulation with bivalirudin plus a 2- to 4-hour high-dose infusion after percutaneous coronary intervention (PCI)...
15.
Kjoller-Hansen L, Maehara A, Kelbaek H, Matsumura M, Maeng M, Engstrom T, et al.
Circ Cardiovasc Interv
. 2024 Sep;
17(10):e014215.
PMID: 39319453
Background: Lipid content in untreated nonobstructive coronary artery lesions is associated with adverse clinical outcomes, and residual in-stent or stent edge lipid may worsen outcomes after percutaneous coronary intervention (PCI)....
16.
Rosen H, Mohammad M, Jernberg T, James S, Oldgren J, Erlinge D
Lancet Reg Health Eur
. 2024 Sep;
45:101032.
PMID: 39262451
Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce rates of heart failure hospitalisations and cardiovascular death in patients with type 2 diabetes and prior cardiovascular disease. We...
17.
Yndigegn T, Gu T, Grufman H, Erlinge D, Mokhtari A, Ekelund U, et al.
ESC Heart Fail
. 2024 Sep;
11(6):4325-4334.
PMID: 39219224
Aims: Carbohydrate antigen 125 (CA125), a mucin produced by serosal cells in response to mechanical and inflammatory stimuli, has emerged as an important biomarker to guide risk stratification in heart...
18.
Mars K, Humphries S, Leissner P, Jonsson M, Karlstrom P, Lauermann J, et al.
Eur Heart J Cardiovasc Pharmacother
. 2024 Sep;
10(8):708-718.
PMID: 39217445
Aims: In the Randomized Evaluation of Decreased Usage of Beta-Blockers after Acute Myocardial Infarction (REDUCE-AMI) study, long-term beta-blocker use in patients after acute myocardial infarction (AMI) with preserved left ventricular...
19.
Bjerking L, Skak-Hansen K, Heitmann M, Hove J, Haahr-Pedersen S, Engblom H, et al.
Eur Heart J
. 2024 Sep;
46(2):117-128.
PMID: 39217444
Background And Aims: Overtesting of low-risk patients with suspect chronic coronary syndrome (CCS) is widespread. The acoustic-based coronary artery disease (CAD)-score has superior rule-out capabilities when added to pre-test probability...
20.
von Koch S, Koul S, Grimfjard P, Andersson J, Jernberg T, Omerovic E, et al.
Heart
. 2024 Aug;
110(22):1307-1315.
PMID: 39214681
Background: Percutaneous coronary intervention (PCI) is frequently used for patients with chronic coronary syndrome (CCS). However, the role of PCI beyond symptom relief in CCS remains controversial. The objective of...